#ASH18: BeiGene works to bust through the checkpoint crowd with a pivotal readout that proves its PD-1 is better than the rest

With 2 pioneering PD-1s lording it over the 6 approved checkpoints in its class, what difference can 1 more make?

The executive team at BeiGene is glad you asked.

On Monday, the Chinese biotech posted some remarkable results for their pivotal study aimed at gaining a quick OK in China for their PD-1 tislelizumab in treatment-resistant classical Hodgkin’s lymphoma. And they’re taking their best shot at making a case in San Diego that this one could be significantly better than its many rivals.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->